SCHEMBL4549706

SCHEMBL4549706

CCCCOc1c(C(=O)OC)occ(Br)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 4/20 0.42
THRB P10828 4/20 0.42
ESR1 P03372 2/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
CASP1 P29466 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
CYP1A2 P05177 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP2D6 P10635 1/20 0.34
PDE4A P27815 1/20 0.34
HIF1A Q16665 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 2/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4549798 0.88 THRA (0.41) THRATHRBESR1MAOBRAB9A
SCHEMBL2601407 0.85 MAOB (0.41) THRATHRBMAOAMAOBRAB9A
SCHEMBL12997699 0.83 CNR2 (0.40) THRATHRBMAOAMAOBRAB9A
SCHEMBL2601701 0.81 MAOB (0.45) MAOAMAOBRAB9ANPC1CASP1
SCHEMBL17928516 0.78 MAOB (0.42) MAOAMAOBRAB9ANPC1CASP1
SCHEMBL754349 0.78 LMNA (0.50) THRATHRBMAOAMAOBRAB9A
SCHEMBL10238627 0.78 TP53 (0.33) MAOAMAOBRAB9ANPC1CASP1
SCHEMBL14535871 0.75 L3MBTL1 (0.40) RAB9ANPC1SMN1; SMN2MAPTL3MBTL1
SCHEMBL4549708 0.75 MAOA (0.39) MAOAMAOBRAB9ANPC1CASP1
SCHEMBL4545465 0.73 GAA (0.35) SMN1; SMN2KDM4EMAPTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-2540720-B1 1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE DERIVATIVE AND USE OF SAME AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC (JP) 2015-04-15 EP disclosed
EP-2540720-A1 1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-A]PYRAZINE DERIVATIVE AND USE OF SAME AS HIV INTEGRASE INHIBITOR Japan Tobacco, Inc. (JP) 2013-01-02 EP disclosed
US-20120108564-A1 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2008-07-03 US disclosed
US-7211572-B2 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108564-A1 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor IMPDH1, IMPA1, DPYD THRA 3648/4885THRB 3605/4885ESR1 3665/4885
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor DNTT, PNP, NNMT THRA 4656/4885THRB 4483/4885ESR1 1393/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI THRA 3617/4885THRB 3798/4885ESR1 1135/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI THRA 3617/4885THRB 3798/4885ESR1 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.